Processa Pharmaceuticals (PCSA) Tax Provisions (2012 - 2021)
Processa Pharmaceuticals' (PCSA) quarterly Tax Provisions came in at -$181752.0 in Q4 2021, up 74.57% YoY from -$104116.6 in Q4 2020, and down 48.44% on a QoQ basis from -$122442.0 in Q3 2021.
Processa Pharmaceuticals (PCSA) Tax Provisions (2012 - 2021) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 8 years of Tax Provisions data on file, last reported at -$181752.0 in Q4 2021.
- Quarterly Tax Provisions rose 74.57% year-over-year to -$181752.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$530611.0 (up 46.99% YoY) and the FY2025 annual result came in at -$2.8 million, down 476.44% from the prior year.
- Tax Provisions retreated to -$181752.0 in Q4 2021, from -$122442.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $260514.0 in Q4 2017 to a low of -$714598.0 in Q4 2020.
- A 5-year average of -$154364.7 and a median of -$134319.0 in 2018 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2018 — Tax Provisions plunged 10879.54% — and 2021, when it jumped 74.57%.
- Tracing PCSA's Tax Provisions over 5 years: stood at $260514.0 in 2017, then slumped by 150.47% to -$131469.0 in 2018, then declined by 22.13% to -$160564.0 in 2019, then sank by 345.05% to -$714598.0 in 2020, then jumped by 74.57% to -$181752.0 in 2021.
- The last three Tax Provisions figures came in at -$181752.0 (Q4 2021), -$122442.0 (Q3 2021), and -$137169.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -181,752.00 |
| Sep 30, 2021 | -122,442.00 |
| Jun 30, 2021 | -137,169.00 |
| Mar 31, 2021 | -89,248.00 |
| Dec 31, 2020 | -714,598.00 |
| Sep 30, 2020 | -70,457.00 |
| Jun 30, 2020 | -87,835.00 |
| Mar 31, 2020 | -128,129.00 |
| Dec 31, 2019 | -160,564.00 |
| Sep 30, 2019 | -141,251.00 |
| Jun 30, 2019 | -170,602.00 |
| Mar 31, 2019 | -130,299.00 |
| Dec 31, 2018 | -131,469.00 |
| Sep 30, 2018 | -212,015.00 |
| Jun 30, 2018 | -277,783.00 |
| Mar 31, 2018 | -281,534.00 |
| Dec 31, 2017 | 260,514.00 |
| Sep 30, 2017 | -1,931.00 |
| Dec 31, 2015 | -25.00 |
| Sep 30, 2015 | -25.00 |